How does A128940's PE Ratio compare to its peers?

A128940 is good value based on its Price-To-Earnings Ratio (19.6x) compared to the peer average (40.8x).

How does A128940's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

A128940 is expensive based on its Price-To-Earnings Ratio (19.6x) compared to the KR Pharmaceuticals industry average (14.6x).

What is A128940's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A128940 is good value based on its Price-To-Earnings Ratio (19.6x) compared to the estimated Fair Price-To-Earnings Ratio (19.7x).

What is the Fair Price of A128940 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A128940 (₩285000) is trading below our estimate of [[fair value]] (₩581701.6)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Hanmi Pharm (KOSE:A128940) - Stock Price, News & Analysis

A128940 Stock Overview

A biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. More details

A128940 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	5/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 51% below our estimate of its fair value

Earnings are forecast to grow 7.38% per year

Earnings grew by 80.8% over the past year

Analysts in good agreement that stock price will rise by 40.4%

Risk Analysis

No risks detected for A128940 from our risk checks.

Hanmi Pharm. Co., Ltd. Competitors

Daewoong Pharmaceutical

KOSE:A069620

₩1.5t

ST PharmLtd

KOSDAQ:A237690

₩1.8t

Yuhan

KOSE:A000100

₩9.0t

Chong Kun Dang Pharmaceutical

KOSE:A185750

₩1.2t

Price History & Performance

Summary of all time highs, changes and price drops for Hanmi Pharm
Historical stock prices
Current Share Price	₩285,000.00
52 Week High	₩377,000.00
52 Week Low	₩258,000.00
Beta	0.47
11 Month Change	-18.69%
3 Month Change	-1.04%
1 Year Change	-3.42%
33 Year Change	13.28%
5 Year Change	-4.65%
Change since IPO	356.47%

Risks To Shareholder Returns Are Elevated At These Prices For Hanmi Pharm. Co., Ltd. (KRX:128940)

Nov 19

Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Nov 01

Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?

Oct 17

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Hanmi Pharm. Co., Ltd. (KRX:128940)

Nov 19

Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Nov 01

Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?

Oct 17

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate

Aug 16

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 24

Shareholder Returns

	A128940	KR Pharmaceuticals	KR Market
7D	-15.9%	-9.2%	-2.8%
1Y	-3.4%	8.0%	-3.4%

Return vs Industry: A128940 underperformed the KR Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: A128940 matched the KR Market which returned -4.4% over the past year.

Price Volatility

Is A128940's price volatile compared to industry and market?
A128940 volatility
A128940 Average Weekly Movement	8.0%
Pharmaceuticals Industry Average Movement	5.5%
Market Average Movement	5.7%
10% most volatile stocks in KR Market	11.5%
10% least volatile stocks in KR Market	2.7%

Stable Share Price: A128940 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A128940's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1973	2,273	Jae-Hyun Park	www.hanmipharm.com

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers.

Hanmi Pharm. Co., Ltd. Fundamentals Summary

How do Hanmi Pharm's earnings and revenue compare to its market cap?
A128940 fundamental statistics
Market cap	₩3.61t
Earnings (TTM)	₩184.38b
Revenue (TTM)	₩1.57t

19.6x

P/E Ratio

2.3x

P/S Ratio

Is A128940 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A128940 income statement (TTM)
Revenue	₩1.57t
Cost of Revenue	₩693.61b
Gross Profit	₩875.17b
Other Expenses	₩690.79b
Earnings	₩184.38b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	14.54k
Gross Margin	55.79%
Net Profit Margin	11.75%
Debt/Equity Ratio	41.8%

How did A128940 perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

5%

Payout Ratio

A128940 Stock Overview

Rewards

Risk Analysis

Hanmi Pharm. Co., Ltd. Competitors

KOSE:A069620

₩1.5t

KOSDAQ:A237690

₩1.8t

KOSE:A000100

₩9.0t

KOSE:A185750

₩1.2t

Price History & Performance

Recent News & Updates

Risks To Shareholder Returns Are Elevated At These Prices For Hanmi Pharm. Co., Ltd. (KRX:128940)

Investor sentiment deteriorates as stock falls 16%

Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Hanmi Pharm. Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Hanmi Pharm. Co., Ltd. (KRX:128940)

Investor sentiment deteriorates as stock falls 16%

Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Hanmi Pharm. Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate

Pinning Down Hanmi Pharm. Co., Ltd.'s (KRX:128940) P/E Is Difficult Right Now

Hanmi Pharm. Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024

Do Hanmi Pharm's (KRX:128940) Earnings Warrant Your Attention?

Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Consensus EPS estimates increase by 10%

Hanmi Pharm. Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up

Now 21% undervalued after recent price drop

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Now 22% undervalued

New minor risk - Shareholder dilution

Hanmi Pharm. Co., Ltd. to Report Q4, 2023 Results on Feb 02, 2024

Upcoming dividend of ₩490 per share at 0.2% yield

Consensus EPS estimates increase by 10%

Hanmi Pharm. Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

Investor sentiment improves as stock rises 20%

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus EPS estimates fall by 12%

Hanmi Pharm. Co., Ltd. to Report Q2, 2023 Results on Jul 28, 2023

First quarter 2023 earnings released: EPS: ₩3,467 (vs ₩1,566 in 1Q 2022)

Consensus EPS estimates increase by 24%

Investor sentiment improves as stock rises 19%

Full year 2022 earnings: EPS exceeds analyst expectations

Upcoming dividend of ₩490 per share

Less than half of directors are independent

Consensus EPS estimates increase by 13%

Now 25% undervalued after recent price drop

Consensus forecasts updated

Consensus EPS estimates increase by 28%

Less than half of directors are independent

Now 22% undervalued

Upcoming dividend of ₩490 per share

Hanmi Pharmaceutical Finds New Innovative Potential for Efpeglenatide

Price target increased to ₩385,044

Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Hanmi Pharm. Co., Ltd., Annual General Meeting, Mar 26, 2021

New 90-day low: ₩319,000

Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky

New 90-day high: ₩405,000

What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?

New 90-day high: ₩394,000

Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years

New 90-day high: ₩375,000

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

New 90-day high: ₩327,500

Analysts lower EPS estimates to ₩2,279

Analysts update estimates

Price target raised to ₩342,471

New 90-day high - ₩284,500